CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum

• Published in: British journal of cancer Vol. 123; no. 3; pp. 449 - 458
• Main Authors: Hsin, I-Lun, Chiu, Ling-Yen, Ou, Chu-Chyn, Wu, Wen-Jun, Sheu, Gwo-Tarng, Ko, Jiunn-Liang
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.08.2020; Nature Publishing Group
• Subjects: 631/67/1059/153; 631/67/1059/2326; 631/80/474/1624; 631/80/82/39/2346; A549 Cells; AC133 Antigen - genetics; AC133 Antigen - metabolism; Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5 - antagonists & inhibitors; Biodegradation; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; CD44 antigen; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Cell Survival - drug effects; Cell viability; Cytotoxicity; Drug Resistance; Drug Resistance, Neoplasm - drug effects; Epidemiology; Fungal Proteins - administration & dosage; Fungal Proteins - pharmacology; Ganoderma - metabolism; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - pharmacology; Immunomodulation; Immunomodulators; Long-term effects; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Male; Mesenchyme; Metastases; Mice; Molecular Medicine; Oct-4 protein; Oncology; Pemetrexed - administration & dosage; Pemetrexed - pharmacology; Phagocytosis; Proteins; Proteolysis; Stem cells; Tumors; Xenograft Model Antitumor Assays; Xenografts

Background Adaptive drug resistance is an unfavourable prognostic factor in cancer therapy. Pemetrexed-resistant lung cancer cells possess high-metastatic ability via ERK–ZEB1 pathway-activated epithelial–mesenchymal transition. GMI is a fungal immunomodulatory protein that suppresses the survival o...